Challenges associated with metal chelation therapy in alzheimer's disease

Muralidhar L. Hegde, P. Bharathi, Anitha Suram, Chitra Venugopal, Ramya Jagannathan, Pankaj Poddar, Pullabhatla Srinivas, Kumar Sambamurti, Kosagisharaf Jagannatha Rao, Janez Scancar, Luigi Messori, Luigi Zecca, Paolo Zatta

Research output: Contribution to journalReview articlepeer-review

132 Scopus citations


A close association between brain metal dishomeostasis and the onset and/or progression of Alzheimer's disease (AD) has been clearly established in a number of studies, although the underlying biochemical mechanisms remain obscure. This observation renders chelation therapy an attractive pharmacological option for the treatment of this disease. However, a number of requirements must be fulfilled in order to adapt chelation therapy to AD so that the term "metal targeted strategies" seems now more appropriate. Indeed, brain metal redistribution rather than brain metal scavenging and removal is the major goal of this type of intervention. The most recent developments in metal targeted strategies for AD will be discussed using, as useful examples, clioquinol, curcumin, and epigallocatechin, and the future perspectives will also be outlined.

Original languageEnglish (US)
Pages (from-to)457-468
Number of pages12
JournalJournal of Alzheimer's Disease
Issue number3
StatePublished - 2009


  • Alzheimer's disease
  • Clioquinol
  • Cuprizone
  • Metal dishomeostasis
  • Metal ions
  • Nanomedicine
  • Parkinson's disease
  • Polyphenols

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Geriatrics and Gerontology
  • Clinical Psychology


Dive into the research topics of 'Challenges associated with metal chelation therapy in alzheimer's disease'. Together they form a unique fingerprint.

Cite this